Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1356898rdf:typepubmed:Citationlld:pubmed
pubmed-article:1356898lifeskim:mentionsumls-concept:C0026809lld:lifeskim
pubmed-article:1356898lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:1356898lifeskim:mentionsumls-concept:C0043240lld:lifeskim
pubmed-article:1356898lifeskim:mentionsumls-concept:C0013295lld:lifeskim
pubmed-article:1356898lifeskim:mentionsumls-concept:C1704242lld:lifeskim
pubmed-article:1356898lifeskim:mentionsumls-concept:C0041582lld:lifeskim
pubmed-article:1356898lifeskim:mentionsumls-concept:C0019588lld:lifeskim
pubmed-article:1356898lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:1356898lifeskim:mentionsumls-concept:C0231491lld:lifeskim
pubmed-article:1356898lifeskim:mentionsumls-concept:C0172825lld:lifeskim
pubmed-article:1356898pubmed:issue6lld:pubmed
pubmed-article:1356898pubmed:dateCreated1992-10-26lld:pubmed
pubmed-article:1356898pubmed:abstractTextWe examined the anti-ulcer effects of FRG-8813, a new-type histamine H2-receptor antagonist, in chronic ulcer models of rats and mice (W/WV). FRG-8813, given orally twice a day for 7 days, accelerated the healing of gastric or duodenal ulcer induced by acetic acid injection or application at the non-antisecretory doses (0.3 approximately 3 mg/kg). Administration of FRG-8813 to rats with ulcers increased the amounts of mucus in the gastric mucosa. These actions of FRG-8813 were more potent than those of famotidine or cimetidine. In W/WV mice, several ulcers spontaneously developed on gastric mucosa during the 8 weeks after the birth. The ulcers were aggravated by several unknown factors after the ulcer generation in W/WV mice. The aggravation of ulcers was inhibited by the 4-week administration of FRG-8813 with diet at the dose of 1 or 10 mg/kg/day, but was not inhibited by cimetidine at the dose of 100 mg/kg/day. From these results, we suggest that FRG-8813 is able to accelerate the healing of ulcers by antisecretory plus increasing actions on the integrity of the gastric mucosal defense mechanisms; therefore FRG-8813 is expected to be a useful drug for the treatment of gastric or duodenal ulcers in humans.lld:pubmed
pubmed-article:1356898pubmed:languagejpnlld:pubmed
pubmed-article:1356898pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1356898pubmed:citationSubsetIMlld:pubmed
pubmed-article:1356898pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1356898pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1356898pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1356898pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1356898pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1356898pubmed:statusMEDLINElld:pubmed
pubmed-article:1356898pubmed:monthJunlld:pubmed
pubmed-article:1356898pubmed:issn0015-5691lld:pubmed
pubmed-article:1356898pubmed:authorpubmed-author:ShibataMMlld:pubmed
pubmed-article:1356898pubmed:authorpubmed-author:OnoderaSSlld:pubmed
pubmed-article:1356898pubmed:authorpubmed-author:OhnishiHHlld:pubmed
pubmed-article:1356898pubmed:authorpubmed-author:InabaNNlld:pubmed
pubmed-article:1356898pubmed:authorpubmed-author:ChidaYYlld:pubmed
pubmed-article:1356898pubmed:authorpubmed-author:YamauraTTlld:pubmed
pubmed-article:1356898pubmed:issnTypePrintlld:pubmed
pubmed-article:1356898pubmed:volume99lld:pubmed
pubmed-article:1356898pubmed:ownerNLMlld:pubmed
pubmed-article:1356898pubmed:authorsCompleteYlld:pubmed
pubmed-article:1356898pubmed:pagination411-20lld:pubmed
pubmed-article:1356898pubmed:dateRevised2011-7-27lld:pubmed
pubmed-article:1356898pubmed:meshHeadingpubmed-meshheading:1356898-...lld:pubmed
pubmed-article:1356898pubmed:meshHeadingpubmed-meshheading:1356898-...lld:pubmed
pubmed-article:1356898pubmed:meshHeadingpubmed-meshheading:1356898-...lld:pubmed
pubmed-article:1356898pubmed:meshHeadingpubmed-meshheading:1356898-...lld:pubmed
pubmed-article:1356898pubmed:meshHeadingpubmed-meshheading:1356898-...lld:pubmed
pubmed-article:1356898pubmed:meshHeadingpubmed-meshheading:1356898-...lld:pubmed
pubmed-article:1356898pubmed:meshHeadingpubmed-meshheading:1356898-...lld:pubmed
pubmed-article:1356898pubmed:meshHeadingpubmed-meshheading:1356898-...lld:pubmed
pubmed-article:1356898pubmed:meshHeadingpubmed-meshheading:1356898-...lld:pubmed
pubmed-article:1356898pubmed:meshHeadingpubmed-meshheading:1356898-...lld:pubmed
pubmed-article:1356898pubmed:meshHeadingpubmed-meshheading:1356898-...lld:pubmed
pubmed-article:1356898pubmed:meshHeadingpubmed-meshheading:1356898-...lld:pubmed
pubmed-article:1356898pubmed:meshHeadingpubmed-meshheading:1356898-...lld:pubmed
pubmed-article:1356898pubmed:meshHeadingpubmed-meshheading:1356898-...lld:pubmed
pubmed-article:1356898pubmed:year1992lld:pubmed
pubmed-article:1356898pubmed:articleTitle[Effects of FRG-8813, a new-type histamine H2-receptor antagonist, on the healing of gastric and duodenal ulcer in rats and spontaneously ulcerative mice].lld:pubmed
pubmed-article:1356898pubmed:affiliationPharmaceuticals Research Laboratories, Fujirebio, Inc., Tokyo, Japan.lld:pubmed
pubmed-article:1356898pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1356898pubmed:publicationTypeEnglish Abstractlld:pubmed